Introduction {#s1}
============

Patients with type 2 diabetes seem to have increased sensitivity toward ischemia-reperfusion (IR) injury and attenuated ability to activate endogenous cardioprotection against IR injury [@pone.0064093-Ferdinandy1], but the results from clinical [@pone.0064093-Btker1] and experimental studies [@pone.0064093-Jensen1] are not consistent.

Mitochondria are the end-effectors of various cardioprotective strategies. Downregulation of metabolism facilitates cardioprotection [@pone.0064093-Chen1]. Metabolic shut-down and gradual wake-up by extending the endogenous inhibition of mitochondrial respiration from ischemia to initial reperfusion followed by gradual reversal during subsequent reperfusion mediates cardioprotection [@pone.0064093-Burwell1], because the burst of reactive oxygen species (ROS) and Ca^2+^ overload prompted by unmodified postischemic reperfusion are attenuated [@pone.0064093-Yellon1]. Reduced glycolysis rate and inhibition of respiratory complexes during ischemia are inherent parts of ischemic preconditioning (IPC) [@pone.0064093-Vogt1]. Mitochondrial dysfunction is considered inherent to the pathophysiology of type 2 diabetes [@pone.0064093-Lowell1] and may diminish the metabolic flexibility, which is a prerequisite for modification of metabolism to elicit cardioprotection.

We have recently shown that inhibition of mitochondrial metabolism during ischemia and early reperfusion, by blockage of the malate-aspartate shuttle (MAS), elicits a cardioprotective effect similar to IPC [@pone.0064093-Stttrup1]--[@pone.0064093-Dalgas1]. MAS constitutes an important mechanism for transport of reduced equivalents from the cytosol to the mitochondria for oxidation and facilitation of glucose oxidation. Its activity is regulated by substrate availability and specific aspartate/glutamate carrier (AGC) proteins located in the mitochondrial membrane [@pone.0064093-Contreras1]. AGC contributes to an asymmetric distribution of reduced nicotine adenine dinucleotide between the cytosolic and the mitochondrial compartment and consists of two proteins, citrin and aralar, of which aralar is predominant [@pone.0064093-Palmieri1]. Overexpression of aralar has been shown to increase glucose oxidation and mitochondrial activity in pancreatic beta cells [@pone.0064093-Rubi1]. In addition, glutamate transfer across the mitochondrial membrane by the excitatory amino acid transporter 1 (EAAT1) is thought to involve MAS. EAAT1 may account for an increase in MAS activity in hyperthyroid rats [@pone.0064093-Ralphe1], suggesting that it may adapt to various pathological conditions. We have recently demonstrated decreased expression of EAAT1 in Zucker Diabetic Fatty (ZDF) rat hearts [@pone.0064093-Povlsen1]. The influence of diabetes duration on the myocardial glucose metabolism during IR and the integrated MAS expression influencing key metabolic pathways for cardioprotection is unknown.

The aim of the present study was to investigate whether sensitivity toward IR injury in type 2 diabetes was dependent on the duration of diabetes, and if so whether differences in sensitivity were associated with changes in myocardial glucose metabolism during ischemia and reperfusion.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

Animals were handled in accordance with national and institutional guidelines for animal research. The experimental work was approved by the Danish Animal Experiments Inspectorate (license no. 2011/561-2010-C2).

Animals {#s2b}
-------

Male Zucker diabetic fatty (ZDF) rats (homozygote (fa/fa)) and their age-matched lean controls (fa/+) (Charles River Laboratories, Kisslegg, Germany) were studied at ages 6, 12 and 24 weeks corresponding to a prediabetic state, onset of and late type 2 diabetes. The rats did not receive any anti-diabetic treatment. They were fed Purina 5008 diet as recommended by the supplier and housed under controlled conditions with 12∶12 h light-dark cycles.

Animals were subjected to 12--16 hours of fasting before experimental procedures. All rats were anaesthetized with Dormicum® (midazolam, 0.5 mg/kg body weight (bwt), Matrix Pharmaceuticals, Herlev, DK) and Hypnorm® (fentanylcitrate, 0.158 mg/kg bwt and fluanisone, 0.5 mg/kg bwt, Vetapharma Ltd., Leeds, UK) by subcutaneous injection before excision of the heart for Langendorff perfusion or tissue analyses.

Study Design and Experimental Protocol {#s2c}
--------------------------------------

The study consisted of three arms that encompassed the following analyses ([Figure 1](#pone-0064093-g001){ref-type="fig"}):

![Study design and experimental protocol.\
Overview of groups, number of animals (**N**) and experimental protocols. **KH-buffer:** Krebs-Henseleit buffer.](pone.0064093.g001){#pone-0064093-g001}

**I. IR-sensitivity analyses**; IR with determination of infarct size (IS), hemodynamic performance, myocardial microdialysis and exogenous glycolysis rate.

**II. Tracer analyses+postischemic tissue analyses**; IR with determination of glucose uptake rate during stabilization and glucose oxidation rate during stabilization and initial reperfusion+myocardial content of total-glycogen after 30 min reperfusion.

**III. Baseline tissue analyses**; myocardial protein expression of MAS-related proteins+measurement of baseline total-glycogen.

Analysis of Blood Glucose and Plasma Metabolites {#s2d}
------------------------------------------------

Preanesthetic fasting blood samples were drawn on animals included in the IR sensitivity analyses (**I**) for measurements of fasting blood glucose (OneTouch® Ultra Blood Glucose, Lifescan Inc., CA, USA) and plasma insulin (DRG Instruments, Marburg, Germany). Samples were obtained from tail-vein bleeding. Preparation for insulin analyses included collection in heparinized capillary tubes (∼100 µL), centrifugation (5000 RPM for 1 min at ambient temperature), collection of the supernatant and storage at −80°C before analysis with a hypersensitive rat insulin ELISA kit (DRG Instruments, Marburg, Germany). Serum total-cholesterol, triglyceride and free fatty acids were measured on blood samples drawn from the aorta of the animal immediately before excision of the heart. Preparation included centrifugation (3500 RPM for 10 min at 4°C), collection of the supernatant and storage at −80°C until analysis on a Cobas Integra Analyzer (Roche Diagnostics, Rotkreuz, Switzerland).

Isolated Perfused Rat Heart Model {#s2e}
---------------------------------

Hearts **(I+II)** were cannulated *in-situ* without disruption of coronary flow and perfused retrogradely a.m. Langendorff with Krebs-Henseleit (KH) solution (11 mM glucose) at a constant pressure of 80 mmHg, as described in detail previously [@pone.0064093-Lfgren1]. The perfusion protocol consisted of 40 min stabilization, 40 min global ischemia and 120 min reperfusion. Left ventricular function was measured by an intraventricular balloon connected to a pressure transducer and coronary flow (CF) by an inline flowmeter (Hugo Sachs Electronic, March-Hugstetten, DE). Diastolic pressure was set to 5--8 mmHg. Data were acquired and analyzed with Notochord®-hem software (Notocord, Croissy-Sur-Seine, France). Hearts were frozen, sliced and underwent vital staining with 2,3,5-triphenyltetrazoliumchloride to delineate areas of infarction **(I)**. IS was assessed by manual delineation using image analysis software (ImageJ, NIH). Measurements were weighted with the weight of each individual slice. The IS/area-at-risk (IS/AAR) ratio was then calculated for each heart.

Myocardial Microdialysis {#s2f}
------------------------

Myocardial microdialysis was performed on all hearts in the perfusion analyses (**I**) to assess interstitial concentrations of citric acid cycle intermediates and glycolytic end products, as described previously [@pone.0064093-Stttrup1]. In brief, a microdialysis probe (membrane length 4 mm, cut-off 6 Da; AgnTho's AB, Sweden) was inserted into the free left ventricular wall of the myocardium enabling sampling with a perfusion rate of 1 µL/min over 10 min. Perfusion fluid was KH buffer deoxygenated with 95% N~2~ and 5% CO~2~. Microdialysis samples were separated by ultra-performance liquid chromatography using a Waters Xevo TQ-S triple quadrupole tandem mass spectrometer (Waters Corp., Manchester, UK). Analytes were verified using two daughter ions and internal standards when possible [@pone.0064093-Birkler1]. Results were corrected for relative recovery rates that have been determined previously [@pone.0064093-Stttrup1], [@pone.0064093-Birkler1].

Exogenous Glucose Metabolism {#s2g}
----------------------------

Rates of glucose uptake, glycolysis and glucose oxidation were measured using statically labeled tritiated glucose isotopes [@pone.0064093-Bolukoglu1]. A buffer volume of 1500 mL (5 mCi/100 mL) was recirculated. Preexperimental buffer samples were drawn to assess baseline specific activity (SA) pr. µmol glucose in the buffer. Glucose uptake was assessed by ^3^H~2~O production from D-\[2-3H\]-glucose [@pone.0064093-Katz1], [@pone.0064093-Doenst1]. Glycolysis rate was determined by liberated ^3^H~2~O from D-\[5-3H\]-glucose at the enolase step of glycolysis [@pone.0064093-Neely1]. Glucose oxidation was quantified by ^3^H~2~O production by oxidation of D-\[6-3H\]-glucose in the citric acid cycle [@pone.0064093-Bolukoglu1]. Because the buffer was recirculated, samples from the inline flow tube ("arterial" (A)) and the coronary effluent ("venous" (V)) were collected and analyzed to assess ^3^H~2~O production. This was done by separation of labeled glucose from ^3^H~2~O by anion exchange chromatography on AG 1-X8 resin columns (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. The purified ^3^H~2~O was suspended in 10 mL Opti-Phase scintillation solution (Perkin-Elmer, Shelton, CT, USA) and quantified by beta-scintillation on a TriCarb 2900TR liquid scintillation analyzer (Packard, Perkin, IL, USA) in detections pr. minute (dpm). Rates of glucose utilization corrected for heart weight and sampling time [@pone.0064093-Bolukoglu1] were calculated as follows:

Myocardial Total-glycogen {#s2h}
-------------------------

Analyses were done on snap-frozen biopsies removed with scissors from the left ventricle in vivo (**III**) and after 30 minutes of reperfusion (**II**). Total glycogen was determined in triplicates after degradation to glucose using the filter-paper technique and spectrophotometric detection [@pone.0064093-Btker2].

Western Blotting {#s2i}
----------------

Left ventricular biopsies were homogenized in 2 mL lysis-buffer [@pone.0064093-Povlsen1] and subsequently centrifuged for 15 min at 4°C and 1000 G. Gel samples were prepared from the supernatant and total protein concentration determined with a Pierce BCA Protein Assay Reagent (Thermo Fisher Scientific Inc., Rockford, USA).

Samples were run on 12.5% polyacrylamide gels (Criterion Tris-HCl, Bio-Rad, CA, USA) and subsequently transferred to a nitrocellulose membrane. The blots were blocked with milk, washed in PBS-T and incubated with primary antibodies overnight at 4°C. Following incubation with horseradish peroxidase-conjugated secondary antibody (P448, diluted 1∶3000, DAKO, Glostrup, Denmark) antigen-antibody complexes were visualized with enhanced chemiluminiscense system (Amersham Pharmacia Biotech, Denmark). Densitometry of protein bands was performed, and for each gel an identical gel was run and subjected to Coomassie staining to ascertain identical loading or to allow for potential correction for minor differences in loading after scanning and densitometry.

### Antibodies {#s2i1}

The following primary antibodies (rabbit polyclonal) were used: Aralar - (1∶2000) (ab90095, Abcam, Cambridge, UK); Citrin -- (1∶500) (sc-98624, Santa Cruz, CA, USA); EAAT1-- (1∶1000) (ab416, Abcam, Cambridge, UK); GOT1/GOT2-- (1∶1000/1∶2000) (ARP48205_T100/ARP43517_T100); MDH1/MDH2-- (1∶1500/1∶1000) (ARP48284_T100/ARP48286_T100, Aviva Systems Biology, CA, USA) When available, a blocking peptide was used as a negative control.

Statistics {#s2j}
----------

For reasons of clarity all data are reported as mean ± SEM, unless stated otherwise, even when the differences between groups were tested with a non-parametric test. Data were analyzed to assess age effect within control and ZDF groups and the effect of diabetes by comparing ZDF groups with age-matched control groups by two-way ANOVA followed by a pairwise comparison by post hoc Bonferroni modification when appropriate. Non-parametric data were compared with Kruskal-Wallis test. Data containing repeated measurements were analyzed using repeated measurements ANOVA. Calculations were performed using GraphPad Prism (GraphPad Software, CA, USA). P\<0.05 was considered statistically significant.

Results {#s3}
=======

Animal Characteristics {#s3a}
----------------------

Heart-, body weights and biochemical characteristics are summarized in [Table 1](#pone-0064093-t001){ref-type="table"}. ZDF rats had increased body weight compared to their respective controls at 6 and 12 weeks of age, while body weight was decreased at 24 weeks of age. Heart weight was similar in control and ZDF rats at 6 and 12 weeks and significantly lower at 24 weeks. In both control and ZDF rats heart weight increased with age. Heart weight corrected for body weight was smaller in ZDF rats at all ages.

10.1371/journal.pone.0064093.t001

###### Animal characteristics.

![](pone.0064093.t001){#pone-0064093-t001-1}

                                  6 weeks                     12 weeks                                     24 weeks                                                                                                                                             
  ----------------------------- ----------- --------------------------------------------- ------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------
  Body weight (BW), g              179±3       204±6[\*](#nt102){ref-type="table-fn"}        317±3[†](#nt103){ref-type="table-fn"}       362±7[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}       446±4[†](#nt103){ref-type="table-fn"}       423±11[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  Heart weight (HW), mg           748±26                       730±17                       1100±41[†](#nt103){ref-type="table-fn"}                      1101±29[†](#nt103){ref-type="table-fn"}                      1509±64[†](#nt103){ref-type="table-fn"}     1258±32[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  HW/BW, ratio                   4.17±0.11   3.59±0.08[\*](#nt102){ref-type="table-fn"}    3.48±0.13[†](#nt103){ref-type="table-fn"}   3.05±0.07[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}   3.38±0.13[†](#nt103){ref-type="table-fn"}   2.98±0.09[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  B-glucose, mmol/L               4.4±0.1     5.3±0.2[\*](#nt102){ref-type="table-fn"}                      4.7±0.1                    13.1±1.6[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}     5.4±0.1[†](#nt103){ref-type="table-fn"}     23.4±1.5[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  P-insulin, pmol/L               6.4±1.0    331.3±40.7[\*](#nt102){ref-type="table-fn"}                   21.8±5.1                                    298.0±27.9[\*](#nt102){ref-type="table-fn"}                                   66.1±10.4                                    92.1±20.1[†](#nt103){ref-type="table-fn"}
  S-total cholesterol, mmol/L    1.67±0.09                    1.89±0.17                                    1.59±0.06                   3.38±0.13[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}                   2.47±0.33                   7.47±0.60[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  S-triglyceride, mmol/L         0.49±0.03   2.42±0.25[\*](#nt102){ref-type="table-fn"}                    0.51±0.03                   6.57±0.60[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}                   0.74±0.06                   10.68±1.32[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  S-free fatty acid, mmol/L      1.40±0.14   4.55±0.80[\*](#nt102){ref-type="table-fn"}                    1.37±0.12                                   5.54±0.80[\*](#nt102){ref-type="table-fn"}                                    2.36±0.23                   7.75±1.76[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}

Mean±SEM.

p\<0.05 compared to age-matched controls.

p\<0.05 compared to 6 weeks control/ZDF.

Albeit still within the normoglycemic range, preoperative fasting glucose was elevated at 6 weeks in ZDF compared to control rats. At 12 weeks ZDF rats were hyperglycemic with a further increase at 24 weeks. In ZDF rats there was a ∼50 fold increase in insulin at 6 weeks compared to controls and a subsequent decline at 12 and 24 weeks. Total cholesterol, triglyceride and free fatty acids were elevated at 6 weeks, although non-significant for cholesterol, with a further increase at 12 and 24 weeks in ZDF rats. All parameters increased with age in control rats.

Preischemic Cardiac Function {#s3b}
----------------------------

[Figure 2](#pone-0064093-g002){ref-type="fig"} shows preischemic cardiac function. At 6 and 12 weeks control and ZDF hearts had similar left ventricular developed pressure (LVDevP) and CF. ZDF hearts displayed lower intrinsic heart rates (HR) and rate-pressure-product (RPP = HR × LVDevP), although not statistically significant at 6 weeks. At 24 weeks of age there was no difference in RPP, as LVDevP and HR declined in the control group, while LVDevP increased in the ZDF group. The latter was accompanied by a significant increase in CF corrected for HW (CF~corr~).

![Hemodynamic parameters at baseline and during reperfusion.\
Hemodynamic performance during stabilization and reperfusion. Mean±SEM. Closed symbols: Control, Open symbols: ZDF. \* p\<0.05, † p\<0.01, ‡ p\<0.001. **LVDevP**: Left ventricular developed pressure. **HR**: Heart rate. **RPP**: rate-pressure-product. **RPPrec**: % recovery from baseline rate-pressure-product. **CF~corr~**: Coronary flow corrected for heart weight.](pone.0064093.g002){#pone-0064093-g002}

Functional Recovery {#s3c}
-------------------

Changes in LVDevP, RPP, relative recovery of RPP (RPP~rec~; % of baseline), HR, CF and CF~corr~ are shown in [Figure 2](#pone-0064093-g002){ref-type="fig"}.

ZDF hearts had decreased RPP at all ages compared to controls. At 6, but not 12, and 24 weeks LVDevP was decreased, whereas HR was decreased at 12 and 24 weeks. When correcting for baseline RPP there was no difference in RPP~rec~ at 12 weeks in contrast to 6 and 24 weeks. There were no differences in CF and CF~corr~ at 6 and 12 weeks, while both were elevated in ZDF hearts at 24 weeks.

RPP decreased in control hearts from 6 and 12 weeks to 24 weeks (p = 0.0003). In ZDF rats a similar pattern was found between 6 and 24 weeks (p = 0.03), while ZDF hearts recovered better at 12 compared to 6 weeks (p = 0.02). There was a significant decline in CF~corr~ from 6 and 12 weeks to 24 weeks in both control and ZDF hearts.

Infarct Size and Correlation with Blood Glucose {#s3d}
-----------------------------------------------

T2DM significantly altered the development in sensitivity towards IR injury compared to controls. At late diabetes ZDF hearts suffered increased IR injury. At onset of T2DM the injury was decreased ([Figure 3A](#pone-0064093-g003){ref-type="fig"}).

![Infarct size and correlation with blood glucose.\
**A.** Infarct size/area-at-risk ratio (IS/AAR). Black bars: Control, White bars: ZDF. **B.** Correlations between preoperative fasting blood glucose and IS/AAR at prediabetes, onset and late type 2 diabetes mellitus. Mean ± SEM. Circles: ZDF 6 weeks, Squares: ZDF 12 weeks, Triangles: ZDF 24 weeks.](pone.0064093.g003){#pone-0064093-g003}

There was a non-significant increase in IS with increasing age in control hearts. In contrast ZDF hearts had reduced IS at 12 weeks compared to 6 as well as 24 weeks, and IS was significantly higher at 24 than at 6 weeks.

IS correlated inversely with blood glucose concentration at 12 weeks (*r^2^* = 0.51, p = 0.046) and tended to correlate positively at 24 weeks in ZDF rats (*r^2^* = 0.46, p = 0.095) ([Figure 3B](#pone-0064093-g003){ref-type="fig"}). There were no significant correlations between IS and circulating free fatty acids, triglyceride or cholesterol concentrations.

Exogenous Glucose Metabolism {#s3e}
----------------------------

### Preischemically {#s3e1}

Rates of exogenous glucose uptake, glycolysis rate and glucose oxidation did not differ between control and ZDF hearts at 6 weeks ([Figure 4](#pone-0064093-g004){ref-type="fig"}). At 12 and 24 weeks glucose uptake -, glycolysis- and oxidation rates were reduced in ZDF hearts. All rates decreased with increasing age in ZDF hearts.

![Glucose metabolism prior to ischemia-reperfusion.\
Glucose uptake -- glycolysis- and glucose oxidation rates during stabilization. Mean ± SEM. Black bars: Control, White bars: ZDF.](pone.0064093.g004){#pone-0064093-g004}

### Postichemically {#s3e2}

Compared to control hearts glycolysis rate did not differ at 6 weeks, but decreased at 12 and 24 weeks of age ([Figure 5A](#pone-0064093-g005){ref-type="fig"}). Glucose oxidation rates were similar at 6 weeks. At onset of type 2 diabetes (12 weeks) ZDF rats completely shut down their exogenous glucose oxidation during the first few minutes of reperfusion (p = 0.0007) with a subsequent increase to reach control levels between 10--30 minutes of reperfusion (p = 0.12) ([Figure 5B](#pone-0064093-g005){ref-type="fig"}). Glucose oxidation was continuously decreased throughout reperfusion in ZDF rats at late diabetes.

![Glucose metabolism during reperfusion.\
**A**: Glycolysis and **B:** Glucose oxidation rates during reperfusion at 6, 12 and 24 weeks. Mean ± SEM. Closed symbols: Control, Open symbols: ZDF. P-values indicate differences between control and ZDF from 0--5 and 10--30 minutes of reperfusion, respectively.](pone.0064093.g005){#pone-0064093-g005}

Myocardial Total-glycogen in vivo and after Ischemia-reperfusion {#s3f}
----------------------------------------------------------------

In vivo total-glycogen concentrations were similar at 6 and 12 weeks and almost 3-fold increased in ZDF rats at 24 weeks compared to control rats ([Figure 6A](#pone-0064093-g006){ref-type="fig"}). After 30 min of reperfusion there were no differences between control and ZDF at any age ([Figure 6B](#pone-0064093-g006){ref-type="fig"}).

![Myocardial glycogen concentrations.\
Myocardial concentrations of total-glycogen in vivo (**A**) and after ischemia and 30 min reperfusion (**B**) in control and ZDF rats. Mean ± SEM. Black bars: Control, White bars: ZDF. **IR**: ischemia-reperfusion. p\<0.0001 vs. age-matched control and ZDF 6 weeks.](pone.0064093.g006){#pone-0064093-g006}

Interstitial Metabolite Concentrations during IR {#s3g}
------------------------------------------------

Interstitial lactate and pyruvate levels were measurable in all groups during the entire protocol. Fumarate, succinate and malate levels were highest at 12 weeks and quantifiable during the entire protocol in both controls and ZDF rats. At 6 and 24 weeks, concentrations only reached quantitative levels during the last 20 minutes of ischemia and the first 10 minutes of reperfusion. Results for control and ZDF hearts at 12 weeks are shown in [Figure 7](#pone-0064093-g007){ref-type="fig"}.

![Interstitial concentrations of metabolites.\
Interstitial concentrations of glycolytic - and citric acid cycle metabolites measured by myocardial microdialysis during ischemia-reperfusion in control (closed squares) and ZDF (open squares) at 12 weeks. Mean ± SEM. **A:** Lactate, **B:** Pyruvate, **C:** Succinate, **D:** Fumarate, **E:** Malate.](pone.0064093.g007){#pone-0064093-g007}

Interstitial lactate levels were similar in control and ZDF hearts during the entire protocol at 6 weeks. ZDF rats had lower interstitial lactate levels during stabilization and the concentration also tended to be lower during reperfusion at 12 weeks ([Figure 7A](#pone-0064093-g007){ref-type="fig"}). Interstitial lactate was increased during late ischemia and entire reperfusion in ZDF hearts at 24 weeks (p = 0.02).

ZDF rats had increased concentrations of pyruvate, fumarate and malate during ischemia, and in particular at the end of ischemia, compared to controls at 12 weeks, while succinate was non-significantly increased ([Figure 7B--E](#pone-0064093-g007){ref-type="fig"}). During reperfusion malate concentration was increased in ZDF rats, while pyruvate, succinate and fumarate levels were similar. At 6 and 24 weeks there were no differences in pyruvate, fumarate, succinate and malate levels.

Protein Expression of MAS Transporters and Enzymes {#s3h}
--------------------------------------------------

There were no significant alterations in protein expression at 6 and 12 weeks of age, although there was a tendency towards upregulation of EAAT1 and downregulation of aralar and the cytosolic enzymes at 12 weeks. At 24 weeks all transport proteins were downregulated. However, the downregulation of aralar did not reach statistical significance ([Figure 8](#pone-0064093-g008){ref-type="fig"}).

![Expression of proteins involved in the malate-aspartate shuttle.\
Fold change in expression of proteins participating in the malate-aspartate shuttle. Controls are set to 0 at all ages. Bars indicate fold change in ZDF hearts compared to control hearts. **A:** Transporter proteins. **B:** Enzymes. C: Representative western blots. There were no significant changes in expression at 6 and 12 weeks, while citrin and EAAT1 were significantly, and aralar non-significantly, downregulated at 24 weeks of age. Mean ± SEM. **EAAT**: Excitatory Amino Acid Transporter. **ASAT:** Aspartate Amino Acid Transaminase. **MDH:** Malate Dehydrogenase. \*p\<0.05.](pone.0064093.g008){#pone-0064093-g008}

Discussion {#s4}
==========

This study provides two major findings: 1) sensitivity towards ischemia-reperfusion injury in the type 2 diabetic heart is dependent on the duration of the disease with decreased sensitivity at onset and increased sensitivity at a late stage, 2) this finding was associated with differences in glucose metabolism during ischemia and reperfusion depending on the stage of the disease. At onset of diabetes there was a shutdown of mitochondrial glucose oxidation during ischemia and initial reperfusion with a subsequent gradual awakening. In contrast rats with late type 2 diabetes displayed continuously decreased glucose metabolism throughout reperfusion and downregulated expression of MAS proteins indicating a dysfunctional cytosol to mitochondria communication that should have facilitated gradual awakening of glucose oxidation. Our findings substantiate previous studies on diabetes and IR injury demonstrating the influence of early and late diabetes [@pone.0064093-Xu1]--[@pone.0064093-Balakumar1]. In addition our study examines concomitantly the impact of myocardial glucose metabolism, ranging from glucose uptake to mitochondrial oxidation, at different stages of type 2 diabetes on IR sensitivity.

Heart-, bodyweights and biochemical data confirm that ZDF rats develop characteristics similar to unregulated human type 2 diabetes. The characteristics of our animals are comparable to those reported by Wang et al. [@pone.0064093-Wang1]. In addition to hyperlipidemia and hypercholesterolemia, ZDF rats develop several obesity- and hyperglycemia-related complications including arterial hypertension, cardiomyopathy, cardiac hypertrophy and nephropathy [@pone.0064093-Baynes1], [@pone.0064093-Fredersdorf1]. Per se, these complications are associated with alterations in either IR sensitivity and/or the effect of cardioprotective strategies. Hyperlipidemia impairs ischemic tolerance and attenuates the effect of conditioning strategies [@pone.0064093-Kupai1], [@pone.0064093-Ungi1]. The effects of compensated hypertrophy and hypertension on IR sensitivity are currently discussed because increased as well as unaltered sensitivity have been reported, while the effect of preconditioning consistently seems to be maintained [@pone.0064093-SpeechlyDick1], [@pone.0064093-Ebrahim1]. In contrast, IR sensitivity is increased in uremia, while the cardioprotective effect of ischemic preconditioning is maintained or even improved [@pone.0064093-Byrne1], [@pone.0064093-Kocsis1]. All of these conditions may be involved in the mechanisms behind the findings of our study. However, based on our data it seems that the factors triggering the response to IR injury in diabetic hearts are associated with mitochondrial glucose metabolism possibly through the MAS-cycle. The correlation between myocardial infarct size and preoperative blood glucose concentration indicates that the decrease in sensitivity towards IR injury in early and increase in sensitivity in late diabetes is associated with the severity of hyperglycemia. Although not overtly hyperglycemic, prediabetic rats had higher blood glucose than controls and a borderline increase in IR injury at this stage supporting the impact of preoperative circulating glucose concentration. An influence of hyperglycemia on IR injury in the presence of evident diabetes and a dependency on disease duration gain support from previous studies [@pone.0064093-Xu1], [@pone.0064093-Chatham1]--[@pone.0064093-Naito1]. However, these studies have been performed in streptozotocin (STZ) or alloxan induced animal models of type 1 diabetes where the disease, in contrast to type 2 diabetes, develops rapidly without the preceding metabolic abnormalities present in the ZDF rat model. Studies in Goto-Kakizaki (GK) rats, another hereditary animal model of type 2 diabetes, have shown that the dependency of myocardial IR injury on circulating glucose levels is a function of age and associated with concomitant alterations in heart mitochondrial function [@pone.0064093-Oliveira1]. Thus, not only the severity but also the duration of hyperglycemia alters sensitivity against IR injury and other yet unidentified mechanisms may be triggered as the animals develop evident diabetes.

The metabolic phenotype associated with reduced sensitivity against IR injury in early diabetes seem to share features with the mechanisms involved in cardioprotection by IPC, which is associated with optimized energy yield by adaptation of major pathways such as glycolysis, glucose - and fatty acid oxidation. Following initial activation of anaerobic glycolysis, persistent ischemia inhibits glycolysis and glycogenolysis. IPC accentuates this inhibition [@pone.0064093-Vogt1], [@pone.0064093-Finegan1] by a metabolic shut-down during ischemia and very early reperfusion followed by a gradual wake-up of metabolism during subsequent reperfusion [@pone.0064093-Burwell1]. Considered a key mechanism behind not only IPC but also cardioprotective strategies like postconditioning and remote ischemic conditioning, the convergence towards mitochondria as the end-effector of ischemic cardioprotection [@pone.0064093-Yellon1], [@pone.0064093-Halestrap1] is of importance for type 2 diabetes, because mitochondrial dysfunction is regarded as an inherent part of insulin resistance in type 2 diabetes [@pone.0064093-Lowell1]. Mitochondrial dysfunction compromising metabolic flexibility has also been demonstrated with ageing [@pone.0064093-Petersen1], but the nature of the abnormality and whether it varies with diabetes duration is unknown.

In accordance with previous studies we found elevated tissue concentrations of the citric acid cycle intermediates (CAC) succinate, fumarate and malate during IR injury [@pone.0064093-Pisarenko1]--[@pone.0064093-Taegtmeyer1]. More importantly, we demonstrated increased concentrations during ischemia at onset of type 2 diabetes compared to controls consistent with the cardioprotective effect of fumarate recently demonstrated by Ashrafian et al. [@pone.0064093-Ashrafian1] in fumarate hydratase (FH) knock-out mice with reduced IR sensitivity. These mice displayed increased levels of second span CAC intermediates (α-ketoglutarate to oxaloacetate) [@pone.0064093-Randle1], and to compensate for the decreased CAC activity due to FH deficiency they channeled amino acids into the CAC and thereby maintained energetic viability. Our findings are not likely to be caused by a decrease in FH activity, because malate was increased. However, a potential mechanism may be a decreased CAC activity due to decreased consumption of reduced equivalents by the respiratory chain enzymes during early reperfusion. When induced in healthy hearts by respiratory chain enzymes inhibitors, this mechanism induces cardioprotection [@pone.0064093-Chen1], [@pone.0064093-Lesnefsky1], and a reduced TCA cycle flux has recently been demonstrated in diabetic myotubes [@pone.0064093-Gaster1] supporting this assumption. An alternative or coexistent mechanism could be increased amino acid derived anaplerosis, which would maintain energetic viability [@pone.0064093-Bradamante1] and cause an increase in second span metabolites. However, the increased interstitial pyruvate concentration during ischemia in diabetic hearts does not support anaplerosis as a predominant mechanism. The increase in pyruvate concentration rather reflects decreased CAC activity and pyruvate utilization.

Localized in the inner mitochondrial membrane, the MAS constitutes the main pathway for balancing myocardial extra- and intramitochondrial glucose metabolism through translocation of reducing equivalents from the cytosol into the mitochondria. We found decreased expression of ASAT1 and a tendency towards increased expression of the glutamate transporter EAAT1 at onset of diabetes. The association between altered protein expression and dynamic changes in metabolism is unknown. Our findings are consistent with an increased metabolic flexibility at onset of type 2 diabetes allowing initial shut down of glucose oxidation because inhibition of MAS causes attenuated transfer of reduced equivalents and decreased CAC activity during early reperfusion combined with a preserved ability of the shuttle to increase its activity and hence mitochondrial metabolism. An increase in expression of glutamate transporters participating in the MAS has previously been shown to enhance mitochondrial metabolism including glucose oxidation [@pone.0064093-Rubi1]. The increased sensitivity towards IR injury at late diabetes could be a consequence of loss of metabolic flexibility due to exhaustion of the MAS, which showed markedly reduced expression, and severe mitochondrial dysfunction in accordance with a recent human study of cardiac expression of MAS-related proteins on pancreatic islet cells in type 2 diabetes [@pone.0064093-MacDonald1]. These abnormalities obstruct the initial metabolic shutdown followed by a gradual acceleration of glucose oxidation [@pone.0064093-Ussher1] and induce irreversible tissue damage [@pone.0064093-Li1]. A recently published study by Sárközy et al. [@pone.0064093-Srkzy1] confirms that late unregulated diabetes in ZDF rats is associated with extensive changes at the mRNA and protein level of the myocardium. In an exploratory study evaluating ∼15.000 genes in 25 wks old ZDF rats they found profound modifications of the myocardial transcriptome including genes involved in carbohydrate metabolism and membrane transport. Moreover, they demonstrated increased levels of cardiac 3-nitrotyrosine, an indicator of oxidative stress, and regulations of genes related to stress response and oxidative stress, factors that are known to affect IR injury. These and ours findings warrant studies with a mechanistic approach to delineate the pathophysiological consequences of these alterations.

We conducted our experiments in an isolated perfused rat heart model with a circulating glucose concentration of 11 mmol/L and glucose as the sole substrate in the absence of insulin to avoid acute influences of different glucose concentrations and interference from fatty acids (FA) and insulin on IR injury. Sensitivity towards IR injury is substrate dependent with increased injury when metabolizing FA [@pone.0064093-Lopaschuk1], and insulin is an activator of the reperfusion injury salvage kinase pathway, which provides cardioprotection [@pone.0064093-Hausenloy1]. Wang et al. [@pone.0064093-Wang1] demonstrated a similar reduction of sensitivity against IR injury in ZDF hearts at onset of type 2 diabetes irrespective of substrate composition. We chose the ZDF rat because it is a commonly used animal model of type 2 diabetes with the inherent metabolic disarrays, i.e. insulin resistance and basal hyperinsulinemia [@pone.0064093-Leonard1], abnormal glucose metabolism [@pone.0064093-YakubuMadus1] and myocardial mitochondrial dysfunction [@pone.0064093-Bonen1], which may modify the efficacy of cardioprotection.

We demonstrated differences in glycolysis and glucose oxidation by quantification of exogenous glucose metabolism. Endogenous glucose metabolism was assessed by tissue measurements of glycogen concentrations before ischemia and after 30 minutes of reperfusion. Although these measurements showed no differences between control and ZDF rats at onset of type 2 diabetes it is a limitation that this method does not allow temporal assessment of endogenous glycogen metabolism during different phases of reperfusion.

A final limitation of our study is that it is not clear to which extend altered protein expression is associated with dynamic changes in metabolism. Although the evidence for the changes in intermediary metabolism and respiratory capacity remain indirect, we applied a variety of approaches and the totality of data from numerous methods underlies our conclusions.

Conclusions {#s4a}
-----------

In conclusion, the alterations in mitochondrial glucose metabolism in type 2 diabetes are associated with protection against IR injury at onset but detrimental effects in late diabetes mellitus. These findings provide an explanation to previous conflicting results on IR injury in individuals with type 2 diabetes.
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